LETTER

Driving pressure and adjunctive therapies in pulmonary sequelae of COVID-19 patients under invasive ventilation



Jessica González^{1,2}, Iván D. Benítez^{1,2}, Anna Motos^{2,3}, Antoni Torres^{2,3} and Ferran Barbé^{1,2*} on behalf of the CIBERESUCICOVID Group

© 2023 Springer-Verlag GmbH Germany, part of Springer Nature

Dear Editor.

A non-negligible proportion of critical patients affected by coronavirus disease 2019 (COVID-19) and with acute respiratory distress syndrome (ARDS) need invasive mechanical ventilation (IMV) [1]. This population is most at risk of developing respiratory sequelae after hospital discharge, most commonly represented as impairment of carbon monoxide diffusing capacity (D $_{\rm LCO}$) [2]. Predictive factors of lung diffusing capacity (D $_{\rm LCO}$) impairment after IMV due to COVID-19 are unknown.

This is a multicentre, prospective observational study in 51 Spanish intensive care units (ICUs). A total of 861 consecutive COVID-19 patients (confirmed by polymerase chain reaction) who underwent IMV from March 2020 to July 2021 and survived were included. At hospital admission, we collected sociodemographic, anthropometric, comorbidity, and lifestyle data. Moreover, inhospital clinical and biological parameters, ventilatory parameters, and adjunctive therapies at three IMV time points (day one, three and the last day), and lung function and computed tomography findings at follow-up were assessed. Material and methods as well as statistical

analysis are shown in electronic supplementary material (ESM).

The median (p₂₅-p₇₅) time from discharge to followup was 3.5 (2.7-4.7) months. The median age was 61 (53-67) years, and 26.9% were women. The mean (SD) percentage of predicted D_{LCO} at follow-up was 70.3% (18%), with 27.5% of patients with a D_{LCO} <60% (see ESM). The evolution of ventilatory parameters according to D_{LCO} groups is described in the supplemental material. Predictive factors for D_{LCO} < 60% were (1) length of IMV [OR: 1.95 (1.65–2.31, p < 0.001)], (2) age [OR: 1.32 (1.11-1.58, p=0.002)], (3) initial driving pressure (DP at day one of intubation) [OR: 1.23 (1.02–1.47, p = 0.033)], (4) time from symptoms to intubation [OR: 1.15 (0.99-1.35, p = 0.075], (5) prone positioning (PP) [OR: 0.69 (0.46-1.02, p=0.062)], and (6) lung recruitment maneuvres (LRMs) [OR: 0.42 (0.30–0.60, p<0.001)] (Fig. 1). A clinical scoring tool, named CIBERESICU SCORE, was developed considering these predictors (https://trrm. shinyapps.io/CIBERESUCIscore/).

Mechanical ventilation leads to increased mechanical stress and potential lung damage, increasing the risk of ventilator-induced lung injury (VILI) [3]. Relatedly, our results showed that ventilatory parameters and adjunctive therapies that are associated to the protective ventilation such as DP [4], PP, and LRMs [5] were not only associated with mortality but also the development of pulmonary sequelae in surviving severe COVID-19 patients who received IMV.

This study has some limitations. First, there were a large number of patients missing follow-up data, including $D_{\rm LCO}$ measurement, and these patients were excluded from our analysis. However, there were no clinical differences at

Jessica González and Iván D. Benítez contributed equally to this manuscript and are first authors.

The members of the CIBERESUCICOVID Group are listed in the Acknowledgement section of the manuscript.



^{*}Correspondence: febarbe.lleida.ics@gencat.catfebarbe.lleida.ics

¹ Pulmonary Department, Translational Research in Respiratory Medicine, University Hospital Arnau de Vilanova and Santa Maria, IRBLleida, Av. Alcalde Rovira Roure, 80, 25198 Lleida, Spain Full author information is available at the end of the article




Fig. 1 Factors associated with D_{LCO} impairment included in final multivariate model. ORs (95% CIs) are shown as 1-SD changes for continuous predictors. D_{LCO} diffusing capacity for carbon monoxide

baseline or in disease severity between them (supplemental material). Second, this was a short-term follow-up study and probably a proportion of patients will improve D_{LCO} after this first follow-up. However, our score can guide decision making by both policy makers and specialist care professional when planning and designing care and followup plans for critical COVID-19 after hospital discharge. Third, the study included almost all the variants of COVID-19; however, the most recent variant, omicron, was not included due to the recruitment period. Along the same lines, the management of this type of patient has changed throughout the pandemic and the proportion of vaccinated patients in our cohort is very low (0.92%). In addition, we do not have information on symptoms and quality of life to assess the impact of this functional impairment. Further studies are needed to validate our results and our clinical score including new COVID-19 variants and vaccinated

In conclusion, in this large cohort of intubated COVID-19 patients, we identified parameters related to IMV, such as time to intubation, length of IMV, DP, LMRs and PP, directly implicated in an altered $D_{\rm LCO}$ after hospital discharge. For the first time, a scoring tool considering all of these parameters plus age is available for use in daily clinical practice to identify high-risk patients and perform more efficient follow-up. Clinicians could use

this score and its bedside parameters to guide decision making to plan proper and efficient follow-up of these patients after hospital discharge.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1007/s00134-022-06951-3.

Author details

¹ Pulmonary Department, Translational Research in Respiratory Medicine, University Hospital Arnau de Vilanova and Santa Maria, IRBLleida, Av. Alcalde Rovira Roure, 80, 25198 Lleida, Spain. ² CIBER of Respiratory Diseases (CIBERES), Institute of Health Carlos III, Madrid, Spain. ³ Department of Pneumology, Hospital Clinic of Barcelona, August Pi i Sunyer Biomedical Research Institute–IDIBAPS, University of Barcelona, Barcelona, Spain.

Acknowledgements

CIBERESUCICOVID Group:

Jordi de Batlle, Translational Research in Respiratory Medicine, University Hospital Arnau de Vilanova and Santa Maria, IRBLleida, Lleida, Spain. CIBER of Respiratory Diseases (CIBERES), Institute of Health Carlos III, Madrid, Spain. Gerard Torres, Translational Research in Respiratory Medicine, University Hospital Arnau de Vilanova and Santa Maria, IRBLleida, Lleida, Spain. CIBER of Respiratory Diseases (CIBERES), Institute of Health Carlos III, Madrid, Spain. David de Gonzalo-Calvo, Translational Research in Respiratory Medicine, University Hospital Arnau de Vilanova and Santa Maria, IRBLleida, Lleida, Spain. CIBER of Respiratory Diseases (CIBERES), Institute of Health Carlos III, Madrid, Spain. Adrián Ceccato, CIBER of Respiratory Diseases (CIBERES), Institute of Health Carlos III, Madrid, Spain. Adrián Ceccato, CIBER of Respiratory Diseases (CIBERES), Institute of Health Carlos III, Madrid, Spain. Critical Care Center, ParcTaulí Hospital Universitari, Institut d'Investigació i Innovació Parc Taulí 13PT, Sabadell, Spain. Ricard Ferrer, Intensive Care Department, Vall d'Hebron Hospital Universitari. SODIR Research Group, Vall d'Hebron Institut de Recerca (VHIR), Barcelona,

Spain. Jordi Riera, Intensive Care Department, Vall d'Hebron Hospital Universitari. SODIR Research Group, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain. Laia Fernández, CIBER of Respiratory Diseases (CIBERES), Institute of Health Carlos III, Madrid, Spain. Department of Pneumology, Hospital Clinic of Barcelona; August Pi i Sunyer Biomedical Research Institute-IDIBAPS, University of Barcelona, Barcelona, Spain. Rosario Menéndez, CIBER of Respiratory Diseases (CIBERES), Institute of Health Carlos III, Madrid, Spain. Servicio de Neumología, IIS/Hospital Universitario y Politécnico La Fe, Valencia, Spain. José Ángel Lorente, CIBER of Respiratory Diseases (CIBERES), Institute of Health Carlos III. Madrid, Spain, Hospital Universitario de Getafe, Universidad Europea, Madrid, Spain. Oscar Peñuelas, CIBER of Respiratory Diseases (CIBERES), Institute of Health Carlos III, Madrid, Spain. Hospital Universitario de Getafe, Universidad Europea, Madrid, Spain. Dario García-Gasulla, Barcelona Supercomputing Center (BSC), Barcelona, Spain. Oriol Roca, Intensive Care Department, Vall d'Hebron Hospital Universitari, SODIR Research Group, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain. Yhivian Peñasco, Servicio de Medicina Intensiva, Hospital Universitario Marqués de Valdecilla, Santander, Spain. Pilar Ricart, Servei de Medicina Intensiva, Hospital Universitari Germans Trias, Badalona, Spain. Maria Cruz Martin Delgado, Hospital Universitario Torrejón, Madrid, Spain. Luciano Aguilera, Servicio de Anestesiología y Reanimación, Hospital Universitario Basurto, Bilbao, Spain. Alejandro Rodríguez, Critical Care Department, Hospital Joan XXIII, Tarragona, Spain. Maria Victoria Boado Varela, Servicio de Medicina Intensiva, Hospital de Cruces, Baracaldo, Vizcaya, Spain. Felipe Pérez-García, Servicio de Análisis Clínicos, Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Spain. Juan Carlos Pozo-Laderas, UGC-Medicina Intensiva, Hospital Universitario Reina Sofia, Instituto Maimonides IMIBIC, Córdoba, Spain. Jordi Solé-Violan, Critical Care Department, Hospital Dr. Negrín Gran Canaria, Las Palmas, Gran Canaria, Spain. Universidad Fernando Pessoa, Canarias, Spain. Feran Roche-Campo, Hospital Verge de la Cinta, Tortosa, Tarragona, Spain. Mariana Andrea Novo, Servei de Medicina Intensiva, Hospital Universitari Son Espases, Palma de Mallorca, Illes Balears, Spain. José Barberán, Hospital Universitario HM Montepríncipe, Universidad San Pablo-CEU, Madrid, Spain. Rosario Amaya Villar, Intensive Care Clinical Unit, Hospital Universitario Virgen de Rocío, Sevilla, Spain. José Garnacho-Montero, Intensive Care Clinical Unit, Hospital Universitario Virgen Macarena, Seville, Spain. José M. Gómez, Hospital General Universitario Gregorio Marañón, Madrid, Spain. Aaron Blandino Ortiz, Servicio de Medicina Intensiva, Hospital Universitario Ramón y Cajal, Madrid, Spain. Luis Tamayo Lomas, Critical Care Department, Hospital Universitario Río Hortega de Valladolid, Valladolid, Spain. Alejandro Úbeda, Servicio de Medicina Intensiva, Hospital Punta de Europa, Algeciras, Spain. Mercedes Catalán-González, Department of Intensive Care Medicine, Hospital Universitario 12 de Octubre, Madrid, Spain. Angel Sánchez-Miralles, Hospital de Sant Joan d'Alacant, Alacant, Spain. Ignacio Martinez Varela, Critical Care Department, Hospital Universitario Lucus Augusti, Lugo, Spain. Ruth Noemí Jorge Garcia, Intensive Care Department, Hospital Nuestra Señora de Gracia, Zaragoza, Spain. Nieves Franco, Hospital Universitario de Móstoles, Madrid, Spain. Victor D. Gumucio-Sanguino, Department of Intensive Care. Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain. Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain. Elena Bustamante-Munguira, Department of Intensive Care Medicine, Hospital Clínico Universitario Valladolid, Valladolid, Spain. Luis Jorge Valdivia, Hospital Universitario de León, León, Spain. Jesús Caballero, Critical Care Department, Hospital Universitari Arnau de Vilanova; IRBLleida, Lleida, Spain. Elena Gallego, Unidad de Cuidados Intensivos, Hospital Universitario San Pedro de Alcántara, Cáceres, Spain. Amalia Martínez de la Gándara, Hospital Universitario Infanta Leonor, Madrid, Spain. Alvaro Castellanos-Ortega, Servicio de medicina intensiva. Hospital Universitario y Politécnico La Fe, Valencia, Spain. Josep Trenado, Servicio de Medicina Intensiva, Hospital Universitario Mútua de Terrassa, Terrassa, Barcelona, Spain. Judith Marin-Corral, Critical Care Department, Hospital del Mar-IMIM, Barcelona, Spain. Guillermo M Albaiceta, CIBER of Respiratory Diseases (CIBERES), Institute of Health Carlos III, Madrid, Spain. Departamento de Biología Funcional. Instituto Universitario de Oncología del Principado de Asturias, Universidad de Oviedo; Instituto de Investigación Sanitaria del Principado de Asturias, Hospital Central de Asturias, Oviedo, Spain. Maria del Carmen de la Torre, Hospital de Mataró de Barcelona, Spain. Ana Loza-Vázquez, Unidad de Medicina Intensiva, Hospital Universitario Virgen de Valme, Sevilla, Spain. Pablo Vidal, Complexo Hospitalario Universitario de Ourense, Ourense, Spain. Jose M. Añón, CIBER of Respiratory Diseases (CIBERES), Institute of Health Carlos III, Madrid, Spain. Servicio de Medicina Intensiva. Hospital Universitario La Paz, IdiPAZ, Madrid, Spain. Cristina

Carbajales Pérez, Intensive Care Unit, Hospital Álvaro Cunqueiro, Vigo, Spain. Victor Sagredo, Hospital Universitario de Salamanca, Salamanca, Spain. Nieves Carbonell, Intensive Care Unit, Hospital Clínico y Universitario de Valencia, Valencia, Spain. Lorenzo Socias, Intensive Care Unit, Hospital Son Llàtzer, Palma de Mallorca, Illes Balears, Spain. Carme Barberà, Hospital Santa Maria; IRBLleida, Lleida, Spain. Angel Estella, Intensive Care Unit, University Hospital of Jerez. Medicine Department University of Cadiz. INIBICA, Spain. Emili Diaz, Department of Medicine, Universitat Autònoma de Barcelona (UAB); Critical Care Department, Corporació Sanitària Parc Taulí, Sabadell, Barcelona, Spain. Sally Santisteve, Translational Research in Respiratory Medicine, University Hospital Arnau de Vilanova and Santa Maria, IRBLleida, Lleida, Spain. CIBER of Respiratory Diseases (CIBERES), Institute of Health Carlos III, Madrid, Spain. Adriano D. S. Targa, Translational Research in Respiratory Medicine, University Hospital Arnau de Vilanova and Santa Maria, IRBLleida, Lleida, Spain. CIBER of Respiratory Diseases (CIBERES), Institute of Health Carlos III, Madrid, Spain. Clara Gort-Paniello, Translational Research in Respiratory Medicine, University Hospital Arnau de Vilanova and Santa Maria, IRBLleida, Lleida, Spain. CIBER of Respiratory Diseases (CIBERES), Institute of Health Carlos III, Madrid, Spain. Anna Moncusí-Moix, Translational Research in Respiratory Medicine, University Hospital Arnau de Vilanova and Santa Maria, IRBLleida, Lleida, Spain. CIBER of Respiratory Diseases (CIBERES), Institute of Health Carlos III, Madrid, Spain. Maria Aquilà, Translational Research in Respiratory Medicine, University Hospital Arnau de Vilanova and Santa Maria, IRBLleida, Lleida, Spain. CIBER of Respiratory Diseases (CIBERES), Institute of Health Carlos III, Madrid, Spain. Fatty Seck, Translational Research in Respiratory Medicine, University Hospital Arnau de Vilanova and Santa Maria, IRBLleida, Lleida, Spain. CIBER of Respiratory Diseases (CIBERES), Institute of Health Carlos III, Madrid, Spain.

Author contributions

Conceptualization (JG, IDB, FB), data curation (IDB), formal analysis (IDB), funding acquisition (AT, FB), investigation (all), methodology (JG, IDB, AM, AT, FB), project administration (AT, FB), supervision (AT, FB), writing—original draft (JG, IDB), and writing—review and editing (all). All authors provided final approval of the version submitted for publication.

Funding

Financial support was provided by Instituto de Salud Carlos III (CIBERESUCI-COVID, COV20/00110), with co-funding from Fondo Europeo de Desarrollo Regional (FEDER), "Una manera de hacer Europa", Centro de Investigación Biomédica en Red – Enfermedades Respiratorias (CIBERES); Donation Program "estar preparados", UNESPA, Madrid, Spain; and Fundación Francisco Soria Melguizo (Madrid, Spain). JdB acknowledges receiving financial support from the Instituto de Salud Carlos III (ISCIII; Miguel Servet 2019: CP19/00108), with co-funding from the European Social Fund (ESF), "Investing in your future". DdGC acknowledges receiving financial support from the Instituto de Salud Carlos III (ISCIII; Miguel Servet 2019: CP20/00041), with co-funding from the European Social Fund (ESF), "Investing in your future". None of the funding sources had a role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the article for publication.

Declarations

Conflicts of interest

The authors declare no conflicts of interest.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Accepted: 5 December 2022 Published: 25 January 2023

References

 Wunsch H (2020) Mechanical ventilation in COVID-19: interpreting the current epidemiology. Am J Respir Crit Care Med 202:1–4

- González J, Benítez ID, Carmona P et al (2021) Pulmonary function and radiologic features in survivors of critical COVID-19: a 3-month prospective cohort. Chest 160:187–198
- Marini JJ, Gattinoni L (2020) Management of COVID-19 respiratory distress. JAMA J Am Med Assoc 323(22):2329–2330
- Boscolo A, Sella N, Lorenzoni G et al (2021) Static compliance and driving pressure are associated with ICU mortality in intubated COVID-19 ARDS. Crit Care 25:263
- Van der Zee P, Gommers D (2019) Recruitment maneuvers and higher PEEP, the so-called open lung concept, in patients with ARDS. Crit Care 23:73